Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069–1086
2. Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580
3. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed October 5, 2020
4. Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714–1768
5. Millsop JW, Wang EA, Fazel N (2017) Etiology, evaluation, and management of xerostomia. Clin Dermatol. 35(5):468–476
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献